logo
Heritage Distilling Co. Cocoa Bomb Chocolate Whiskey Named 'World's Best Flavored Whiskey' at Whisky Magazine's World Whiskies Awards

Heritage Distilling Co. Cocoa Bomb Chocolate Whiskey Named 'World's Best Flavored Whiskey' at Whisky Magazine's World Whiskies Awards

Yahoo27-03-2025

Marks an unprecedented third win for Heritage Distilling Co. in this prestigious categoryGIG HARBOR, Wash., March 27, 2025 (GLOBE NEWSWIRE) -- Heritage Distilling Holding Company, Inc. ("HDC" or "Heritage") (Nasdaq: CASK), a leading craft distiller of innovative premium brands, announced that its Cocoa Bomb Chocolate Whiskey was named 'World's Best Flavored Whiskey' by Whisky Magazine at the World Whiskies Awards in London, England. Previously, Heritage has won Whisky Magazine's 'World's Best Flavored Whiskey' twice for Brown Sugar Bourbon.
"We are incredibly proud to have earned this prestigious global honor for the third time from the tasting panel at Whisky Magazine,' said Justin Stiefel, CEO and co-founder of Heritage. 'Cocoa Bomb Chocolate Whiskey's global flavor award from one of the most respected whiskey publications in the world is a testament to the dedication and craftsmanship our team pours into every bottle. Every whiskey we create captures the essence of true, authentic flavors, and this latest global award is proof of our efforts. To win this global category award for a third time is unprecedented in the global spirits industry, further solidifying our leading position in the rapidly growing flavored whiskey market.'
Cocoa Bomb Chocolate Whiskey is bottled at 75-proof and is naturally flavored. No artificial flavors, sweeteners or ingredients are used. Flavor notes include a burst of semi-sweet dark cocoa, cocoa nibs and a rich chocolate nose with a smooth signature whiskey finish. Cocoa Bomb Chocolate Whiskey is available in 750 ml and 50 ml size formats at select spirits retailers. It is also available in HDC tasting rooms and online for direct-to-consumer orders.
For more information about Heritage and its suite of award-winning products, visit: heritagedistilling.com.
About Heritage Distilling Holding Company, Inc.Heritage is one of the premier independent craft distilleries in the United States, offering a diverse range of whiskeys, vodkas, gins, rums, and ready-to-drink canned cocktails. For ten consecutive years, the American Distilling Institute has recognized Heritage as North America's most awarded craft distillery out of more than 2,600 producers. In addition to winning the 'World's Best Flavored Whiskey' award an unprecedented three times by Whiskey Magazine, the company has also earned numerous Best of Class, Double Gold, and Gold medals at prestigious national and international spirits competitions. As a prominent player in the rapidly growing $288 billion spirits market, Heritage ranks among the largest craft spirits producers on the West Coast by revenue. The company is expanding its national footprint through multiple sales channels, including wholesale, e-commerce, direct-to-consumer (DTC) in 46 states, on-premises venues at its distilleries and tasting rooms, a subscription-based program, and the innovative Tribal Beverage Network (TBN). The TBN initiative is a groundbreaking collaboration with Native American tribes, aimed at developing Heritage-branded distilleries, unique brands, and tasting rooms tailored to patrons of tribal casinos and entertainment venues, creating meaningful economic and social benefits for participating tribes while offering them an opportunity to strengthen their sovereignty and create new amenities for their clients and customers. It reflects Heritage's commitment to innovation, community engagement, and sustainable growth. Heritage also raises donations for carefully vetted non-profits that support active-duty, retired, and injured special operations heroes, veterans, first responders, and their families through its Salute Series line of super-premium whiskeys. Learn more at HeritageDistilling.com.
Forward-Looking Statements
This press release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as "aims," "anticipates," "believes," "could," "estimates," "expects," "forecasts," "goal," "intends," "may," "plans," "possible," "potential," "seeks," "will," and variations of these words or similar expressions that are intended to identify forward-looking statements. Any such statements in this press release that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements include, without limitation, statements regarding anticipated results or benefits anticipated from awards or accolades received for Heritage's products and the implications that may come from it.
Any forward-looking statements in this press release are based on Heritage's current expectations, estimates and projections only as of the date of this release and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the risks of slowing growth for its online eCommerce sales, interruptions in that market segment, or the availability and pricing of bulk bourbon for its products. These and other risks concerning Heritage's programs and operations are described in additional detail in its registration statement on Form S-1, and its quarterly 10-Q filings, which are on file with the SEC. Heritage explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.
Investor Contact(800) 595-3550ir@heritagedistilling.com
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/95a03829-84c2-45ad-8dea-0fcd61baffb3

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

What Texas Instruments Capital Strength Means for Its Dividend
What Texas Instruments Capital Strength Means for Its Dividend

Yahoo

time19 minutes ago

  • Yahoo

What Texas Instruments Capital Strength Means for Its Dividend

Texas Instruments Incorporated (NASDAQ:TXN) is one of the Best Stocks to Buy for Dividends. A robotic arm in the process of assembling a complex circuit board - showing the industrial scale the company operates at. The company follows a strong business model centered on analog and embedded processing products, supported by its long-lasting competitive strengths. Another key part of its strategy to drive long-term growth in free cash flow per share is its disciplined approach to capital allocation. This includes careful selection of research and development projects, building new capabilities, investing in manufacturing capacity, evaluating potential acquisitions, and returning capital to shareholders. Texas Instruments Incorporated (NASDAQ:TXN)'s strategy also focuses on efficiency, which it defines as consistently aiming to generate greater results for every dollar spent. This approach emphasizes directing investments toward the most impactful areas to support the long-term growth of free cash flow per share, rather than simply cutting costs to the bare minimum. For shareholders, this commitment to efficiency is expected to support revenue growth, stronger gross margins, careful management of R&D and SG&A expenses, healthy free cash flow margins, and ultimately, an increase in free cash flow per share. Texas Instruments Incorporated (NASDAQ:TXN) currently offers a quarterly dividend of $1.36 per share. Overall, the company has raised its payouts for 21 consecutive years. In the past five years, it has raised its payouts at an annual average rate of over 9%, which is considered a solid pace in the tech sector. As of June 25, TXN has a dividend yield of 2.65%. While we acknowledge the potential of TXN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure. None. Sign in to access your portfolio

Akebia Therapeutics (AKBA) Grants Stock Options to New Employees
Akebia Therapeutics (AKBA) Grants Stock Options to New Employees

Yahoo

time40 minutes ago

  • Yahoo

Akebia Therapeutics (AKBA) Grants Stock Options to New Employees

Akebia Therapeutics, Inc. (NASDAQ:AKBA) is one of the 10 best healthcare penny stocks to buy according to analysts. On June 2, the company reported that it had granted options to purchase an aggregate of 137,000 shares of its common stock to three newly hired employees on May 30, 2025. yezry/ These options were given as inducement material to each employee entering into employment with Akebia. The company stated that the grants were made per Nasdaq Listing Rule 5635(c)(4). Also, the exercise price for the options is $3.03 per share, which was the closing price of the company's common stock on the grant date. The stock options vest over a four-year period, with 25% of the shares vesting on the first anniversary of the grant date. The remaining 75% will vest quarterly thereafter, provided the new employee remains with Akebia. The options are the latest after Akebia granted 148,000 shares of its common stock to eight newly hired employees on April 30, 2025. Akebia Therapeutics, Inc. (NASDAQ:AKBA) is a biopharmaceutical company focused on developing treatments for kidney-related diseases. It develops and sells two main products: Auryxia, used to manage phosphorus levels and treat iron deficiency anemia in patients with chronic kidney disease (CKD), and Vafseo, an oral medication for anemia associated with CKD. While we acknowledge the potential of AKBA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: Goldman Sachs Energy Stocks: 10 Stocks to Buy and 10 Best AI Stocks to Buy According to Billionaire David Tepper. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Ardelyx (ARDX) Appoints New Chief Business and HR Officers
Ardelyx (ARDX) Appoints New Chief Business and HR Officers

Yahoo

time40 minutes ago

  • Yahoo

Ardelyx (ARDX) Appoints New Chief Business and HR Officers

Ardelyx, Inc. (NASDAQ:ARDX) is one of the 10 best healthcare penny stocks to buy according to analysts. On June 2, the company announced two key appointments to its leadership team. Mike Kelliher, who joined the company in March 2024, was promoted from his previous role as Executive Vice President, Corporate Development and Strategy to Chief Business Officer (CBO). James P. Brady joined Ardelyx as the new Chief Human Resources Officer (CHRO). Both Kelliher and Brady report directly to Mike Raab, the company's President and CEO. A pharmacy worker distributing prescription medicines to patientsreceiving treatment for oncology, cardiovascular, renal, metabolism and respiratory diseases. Ardelyx said that these appointments are part of its strategy to strengthen its leadership team. The move, the company stated, is crucial to advancing its commercial and clinical programs. 'As we continue to grow and evolve our business, it is imperative that we have high caliber leaders, like Mike and Jamie, who will enable us to accelerate our momentum and deliver long-term impact for patients and shareholders,' said Raab. The CEO highlighted Kelliher's experiences, business intuition, and leadership as bringing 'incredible value' to Ardelyx. On the other hand, he expressed excitement about welcoming Brady, emphasizing his talent as an HR executive and his extensive experience in people development, which will be influential in advancing key business initiatives and talent strategies. Ardelyx, Inc. (NASDAQ:ARDX) is a biopharmaceutical company. It discovers, develops, and commercializes first-in-class medicines for gastrointestinal and kidney diseases. Its key products include IBSRELA (for irritable bowel syndrome with constipation) and XPHOZAH (a phosphate absorption inhibitor for chronic kidney disease patients on dialysis). Ardelyx serves adult patients in the United States and internationally. While we acknowledge the potential of ARDX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: Goldman Sachs Energy Stocks: 10 Stocks to Buy and 10 Best AI Stocks to Buy According to Billionaire David Tepper. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store